GlassScriptPhysician profile
Heather Ballard
NPI 1538615570
$6,515.32
in general payments reported to CMS, 2019-2025
27 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,337 · 2022: $1,348 · 2023: $1,162 · 2024: $1,377 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,813 · Education: $17.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,812.85 |
| Education | $17.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,328.44 | 2021-2025 | Xifaxan, Trulance, Uceris |
| Abbvie INC. | $1,238.02 | 2021-2025 | |
| Janssen Biotech, INC. | $1,147.68 | 2021-2025 | Stelara, Tremfya, Remicade |
| Ironwood Pharmaceuticals, INC | $389.07 | 2021-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $300.89 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $281.09 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $230.10 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $220.92 | 2021-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $214.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $168.21 | 2021-2024 | |
| Qol Medical, LLC | $141.61 | 2021-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $131.86 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $121.86 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $101.44 | 2024-2025 | Zenpep, Vowst |
| Evoke Pharma, INC. | $77.70 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.29 | 2021-2022 | |
| Celgene Corporation | $66.31 | 2021-2022 | |
| Genzyme Corporation | $52.80 | 2023-2024 | |
| Lilly USA, LLC | $35.15 | 2025 | Omvoh |
| Echosens North America, INC. | $34.06 | 2021-2024 | Fibroscan |
| Nestle Healthcare Nutrition INC. | $31.63 | 2023 | |
| Boston Scientific Corporation | $30.25 | 2022-2023 | Eluvia |
| Ferring Pharmaceuticals INC. | $29.21 | 2023 | Rebyota |
| Axonics, INC. | $17.76 | 2021 | |
| Celltrion USA INC. | $17.74 | 2024 | Zymfentra |
| Ambu INC. | $15.71 | 2021 | |
| Braintree Laboratories, INC. | $13.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.